PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
MRNA vs. ABBV
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between MRNA and ABBV is 0.14, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

MRNA vs. ABBV - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Moderna, Inc. (MRNA) and AbbVie Inc. (ABBV). The values are adjusted to include any dividend payments, if applicable.

-80.00%-60.00%-40.00%-20.00%0.00%20.00%AugustSeptemberOctoberNovemberDecember2025
-71.88%
1.31%
MRNA
ABBV

Key characteristics

Sharpe Ratio

MRNA:

-1.05

ABBV:

0.41

Sortino Ratio

MRNA:

-1.82

ABBV:

0.66

Omega Ratio

MRNA:

0.77

ABBV:

1.10

Calmar Ratio

MRNA:

-0.71

ABBV:

0.51

Martin Ratio

MRNA:

-1.42

ABBV:

1.26

Ulcer Index

MRNA:

46.36%

ABBV:

7.72%

Daily Std Dev

MRNA:

62.64%

ABBV:

23.80%

Max Drawdown

MRNA:

-93.03%

ABBV:

-45.09%

Current Drawdown

MRNA:

-92.97%

ABBV:

-15.05%

Fundamentals

Market Cap

MRNA:

$13.11B

ABBV:

$303.17B

EPS

MRNA:

-$5.86

ABBV:

$2.87

PEG Ratio

MRNA:

0.00

ABBV:

0.41

Total Revenue (TTM)

MRNA:

$2.26B

ABBV:

$41.23B

Gross Profit (TTM)

MRNA:

$1.46B

ABBV:

$30.76B

EBITDA (TTM)

MRNA:

-$2.28B

ABBV:

$17.62B

Returns By Period

In the year-to-date period, MRNA achieves a -18.09% return, which is significantly lower than ABBV's -2.54% return.


MRNA

YTD

-18.09%

1M

-11.21%

6M

-71.88%

1Y

-65.62%

5Y*

10.58%

10Y*

N/A

ABBV

YTD

-2.54%

1M

0.97%

6M

1.31%

1Y

7.92%

5Y*

19.25%

10Y*

15.32%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

MRNA vs. ABBV — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MRNA
The Risk-Adjusted Performance Rank of MRNA is 55
Overall Rank
The Sharpe Ratio Rank of MRNA is 33
Sharpe Ratio Rank
The Sortino Ratio Rank of MRNA is 33
Sortino Ratio Rank
The Omega Ratio Rank of MRNA is 44
Omega Ratio Rank
The Calmar Ratio Rank of MRNA is 88
Calmar Ratio Rank
The Martin Ratio Rank of MRNA is 77
Martin Ratio Rank

ABBV
The Risk-Adjusted Performance Rank of ABBV is 5858
Overall Rank
The Sharpe Ratio Rank of ABBV is 6161
Sharpe Ratio Rank
The Sortino Ratio Rank of ABBV is 5050
Sortino Ratio Rank
The Omega Ratio Rank of ABBV is 5454
Omega Ratio Rank
The Calmar Ratio Rank of ABBV is 6868
Calmar Ratio Rank
The Martin Ratio Rank of ABBV is 6060
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

MRNA vs. ABBV - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Moderna, Inc. (MRNA) and AbbVie Inc. (ABBV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for MRNA, currently valued at -1.05, compared to the broader market-2.000.002.004.00-1.050.41
The chart of Sortino ratio for MRNA, currently valued at -1.82, compared to the broader market-4.00-2.000.002.004.00-1.820.66
The chart of Omega ratio for MRNA, currently valued at 0.77, compared to the broader market0.501.001.502.000.771.10
The chart of Calmar ratio for MRNA, currently valued at -0.71, compared to the broader market0.002.004.006.00-0.710.51
The chart of Martin ratio for MRNA, currently valued at -1.42, compared to the broader market-10.000.0010.0020.0030.00-1.421.26
MRNA
ABBV

The current MRNA Sharpe Ratio is -1.05, which is lower than the ABBV Sharpe Ratio of 0.41. The chart below compares the historical Sharpe Ratios of MRNA and ABBV, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00AugustSeptemberOctoberNovemberDecember2025
-1.05
0.41
MRNA
ABBV

Dividends

MRNA vs. ABBV - Dividend Comparison

MRNA has not paid dividends to shareholders, while ABBV's dividend yield for the trailing twelve months is around 3.67%.


TTM20242023202220212020201920182017201620152014
MRNA
Moderna, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
ABBV
AbbVie Inc.
3.67%3.49%3.82%3.49%3.84%4.41%4.83%3.89%2.65%3.64%3.41%2.54%

Drawdowns

MRNA vs. ABBV - Drawdown Comparison

The maximum MRNA drawdown since its inception was -93.03%, which is greater than ABBV's maximum drawdown of -45.09%. Use the drawdown chart below to compare losses from any high point for MRNA and ABBV. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-92.97%
-15.05%
MRNA
ABBV

Volatility

MRNA vs. ABBV - Volatility Comparison

Moderna, Inc. (MRNA) has a higher volatility of 26.00% compared to AbbVie Inc. (ABBV) at 5.76%. This indicates that MRNA's price experiences larger fluctuations and is considered to be riskier than ABBV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%25.00%AugustSeptemberOctoberNovemberDecember2025
26.00%
5.76%
MRNA
ABBV

Financials

MRNA vs. ABBV - Financials Comparison

This section allows you to compare key financial metrics between Moderna, Inc. and AbbVie Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab